These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23520985)

  • 21. A chemical-biological study reveals C9-type iridoids as novel heat shock protein 90 (Hsp90) inhibitors.
    Dal Piaz F; Vassallo A; Temraz A; Cotugno R; Belisario MA; Bifulco G; Chini MG; Pisano C; De Tommasi N; Braca A
    J Med Chem; 2013 Feb; 56(4):1583-95. PubMed ID: 23362862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity.
    Rowlands MG; Newbatt YM; Prodromou C; Pearl LH; Workman P; Aherne W
    Anal Biochem; 2004 Apr; 327(2):176-83. PubMed ID: 15051534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
    Kung PP; Funk L; Meng J; Collins M; Zhou JZ; Johnson MC; Ekker A; Wang J; Mehta P; Yin MJ; Rodgers C; Davies JF; Bayman E; Smeal T; Maegley KA; Gehring MR
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6273-8. PubMed ID: 18929486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure based design of heat shock protein 90 inhibitors acting as anticancer agents.
    Doddareddy MR; Thorat DA; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN
    Bioorg Med Chem; 2011 Mar; 19(5):1714-20. PubMed ID: 21306907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological evaluation of 2,4-diaminoquinazoline derivatives as novel heat shock protein 90 inhibitors.
    Thorat DA; Doddareddy MR; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1593-7. PubMed ID: 21353544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
    Gunaherath GM; Marron MT; Wijeratne EM; Whitesell L; Gunatilaka AA
    Bioorg Med Chem; 2013 Sep; 21(17):5118-29. PubMed ID: 23859777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.
    Bargiotti A; Musso L; Dallavalle S; Merlini L; Gallo G; Ciacci A; Giannini G; Cabri W; Penco S; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Barbarino M; Pisano C; Giommarelli C; Zuco V; De Cesare M; Zunino F
    Eur J Med Chem; 2012 Jul; 53():64-75. PubMed ID: 22538015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening.
    Abbasi M; Sadeghi-Aliabadi H; Hassanzadeh F; Amanlou M
    J Mol Graph Model; 2015 Sep; 61():186-95. PubMed ID: 26277488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of new Hsp90 inhibitors by structure-based virtual screening.
    Hong TJ; Park H; Kim YJ; Jeong JH; Hahn JS
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4839-42. PubMed ID: 19560353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
    Murray CW; Carr MG; Callaghan O; Chessari G; Congreve M; Cowan S; Coyle JE; Downham R; Figueroa E; Frederickson M; Graham B; McMenamin R; O'Brien MA; Patel S; Phillips TR; Williams G; Woodhead AJ; Woolford AJ
    J Med Chem; 2010 Aug; 53(16):5942-55. PubMed ID: 20718493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based discovery of a new class of Hsp90 inhibitors.
    Barril X; Brough P; Drysdale M; Hubbard RE; Massey A; Surgenor A; Wright L
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5187-91. PubMed ID: 16202589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity.
    Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Ingalls C; Sutherland AG; Sonye JP; Eid CN; Golas J; Liu H; Boschelli F; Hu Y; Vogan E; Levin JI
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2278-82. PubMed ID: 21420297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the hydrophobic region of Hsp90's ATP binding pocket with novel 1,3,5-triazines.
    Lee T; Seo YH
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6427-31. PubMed ID: 24125885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of New Hsp90 Inhibitors: Structure Based Virtual Screening, Molecular Dynamic Simulation, Synthesis and Biological Evaluation.
    Abbasi M; Amanlou M; Aghaei M; Hassanzadeh F; Sadeghi-Aliabadi H
    Anticancer Agents Med Chem; 2021; 21(18):2583-2591. PubMed ID: 33563187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hsp90 inhibitors and drugs from fragment and virtual screening.
    Roughley S; Wright L; Brough P; Massey A; Hubbard RE
    Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular docking study, synthesis and biological evaluation of Schiff bases as Hsp90 inhibitors.
    Dutta Gupta S; Snigdha D; Mazaira GI; Galigniana MD; Subrahmanyam CV; Gowrishankar NL; Raghavendra NM
    Biomed Pharmacother; 2014 Apr; 68(3):369-76. PubMed ID: 24486109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.
    Burlison JA; Avila C; Vielhauer G; Lubbers DJ; Holzbeierlein J; Blagg BS
    J Org Chem; 2008 Mar; 73(6):2130-7. PubMed ID: 18293999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90).
    Radanyi C; Le Bras G; Messaoudi S; Bouclier C; Peyrat JF; Brion JD; Marsaud V; Renoir JM; Alami M
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2495-8. PubMed ID: 18304811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
    Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
    J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and Structure-Activity Studies of 1,3-Dibenzyl-2-aryl imidazolidines as Novel Hsp90 Inhibitors.
    Liu Y; Liu X; Li L; Dai R; Shi M; Xue H; Liu Y; Wang H
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31163701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.